Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vivoryon Therapeutics N.V. (0R3M.L)
Halle, DE
Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutic solutions for Alzheimer's disease. Their primary strategy involves targeting and inhibiting the production of toxic pyroglutamate-Abeta (pGlu-Abeta). The company's lead investigational compound, PQ912, is a small molecule QC inhibitor. This candidate has successfully completed Phase IIb clinical trials for both Alzheimer's disease and cancer. In its preclinical pipeline, Vivoryon is advancing PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor, specifically for cancer treatment. Additionally, the firm is developing a monoclonal antibody designed to enhance the clearance of pGlu-Abeta. Vivoryon Therapeutics maintains a robust network of collaborations, including a research agreement with University Medical Center Schleswig-Holstein focused on cancer immunotherapy, and a partnership with Nordic Bioscience for the clinical advancement of PQ912 in Alzheimer's disease. Further alliances include a research collaboration with the Fraunhofer Institute for cell therapy and immunology, and a strategic regional licensing agreement with Simcere Pharmaceutical Group Ltd. This latter partnership aims to develop and commercialize medicines specifically targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to address Alzheimer's disease. Established in 1997, Vivoryon Therapeutics N.V. is headquartered in Halle, Germany.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.82% | +2.82% | -2.67% | -12.67% | -21.30% | -12.07% | -25.44% | -91.44% | -90.47% | -90.47% | -90.47% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Biotechnology: +1.6%— Q4'25: +100.0% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+58.2% ★ Q4'25: +83.3% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q4'25: +1,864.3% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+3.7% Q4'25: +16.7% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q4'25: -0.01× (vs Q4'23)
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
—
|
—
|
100.00
100.00 – 100.00
|
339.70M
339.70M – 339.70M
+339,699,900.0% YoY
|
—
— – —
-100.0% YoY
|
| EBITDA |
-20.34M
|
-9.03M
|
60.00
60.00 – 60.00
|
203.82M
203.82M – 203.82M
+339,699,900.0% YoY
|
—
— – —
-100.0% YoY
|
| EBIT |
-20.48M
|
-9.18M
|
60.00
60.00 – 60.00
|
203.82M
203.82M – 203.82M
+339,699,900.0% YoY
|
—
— – —
-100.0% YoY
|
| Net Income |
-20.57M
est: -23.43M (+12.2%)
|
-8.85M
est: -18.89M (+53.1%)
|
-18.89M
-18.89M – -18.89M
+0.0% YoY
|
-15.11M
-15.11M – -15.11M
+20.0% YoY
|
-16.19M
-16.19M – -16.19M
-7.1% YoY
|
| SGA |
6.76M
|
4.65M
|
23.00
23.00 – 23.00
|
81.35M
81.35M – 81.35M
+353,683,365.2% YoY
|
—
— – —
-100.0% YoY
|
| EPS |
-0.79
est: -0.90 (+12.2%)
|
-0.33
est: -0.70 (+52.9%)
|
-0.70
-0.70 – -0.70
+0.0% YoY
|
-0.56
-0.56 – -0.56
+20.0% YoY
|
-0.60
-0.60 – -0.60
-7.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael Schaeffer | Chief Business Officer & Executive Director | 341.0K | — |
| Frank T. Weber | MD, CEO, Chief Medical Officer & Executive Director | 329.0K | male |
| Hendrik Liebers | Advisor | 319.2K | — |
| Julia Neugebauer | Head of Investor Relations & Communications, COO & Executive Board Member | 259.0K | — |
| Konrad Glund | Co-Founder & Advisor | 222.1K | — |
| Marcus Irsfeld | Chief Financial Officer & Executive Director | 109.0K | male |
| Manuela Bader | Director of Investor Relations & Communications | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 0R3M.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
